Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Journal of Diabetes|October 7, 2010
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)Erland Erdmann, Robert Spanheimer, Bernard Charbonnel, et al.Journal of Clinical Hypertension (Greenwich, Conn.)|December 3, 2010
Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetesAlfonso Perez, Randal Jacks, Vipin Arora, et al.Current Medical Research and Opinion|October 16, 2009
Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DMAlfonso Perez, Zhen Zhao, Randal Jacks, et al.Vascular Pharmacology|June 3, 2006
Vascular effects of TZDs: new implicationsFlorian Blaschke, Robert Spanheimer, Mehmood Khan, et al.The American Journal of Cardiology|July 7, 2009
Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14)Robert Spanheimer, D John Betteridge, Meng H Tan, et al.Diabetes Care|August 2, 2007
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)Erland Erdmann, Bernard Charbonnel, Robert G Wilcox, et al.Pageof 1